Genetic Risk Information for Alzheimer's Disease
(IDEAL Trial)

Recruiting in Palo Alto (17 mi)

Overseen byRuth Ottman, PhD

Age: 18 - 65

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Columbia University

No Placebo Group

Trial Summary

What is the purpose of this trial?

This study will assess the psychosocial and behavioral impacts of receiving Alzheimer's disease genetic risk assessment incorporating APOE genotypes among Latinos in northern Manhattan. The investigators will conduct a longitudinal, community-based study with a mixed methods design. Participants will be randomized to learn about their lifetime risk of late-onset Alzheimer's disease (AD) based either on (a) Latino ethnicity and family history alone (genotype nondisclosure group), or (b) the same factors plus APOE genotype (genotype disclosure group). Responses will be evaluated at 6 weeks, 9 months, and 15 months after risk assessment. In the quantitative component of the study, the investigators will assess psychosocial outcomes, memory test performance, and health-related behaviors. In the qualitative component of the study, the investigators will investigate the lived experience of receiving personal AD risk information, using a stress and coping theoretical framework.

Research Team

Ruth Ottman, PhD

Principal Investigator

Columbia University

Eligibility Criteria

This trial is for Latinos aged 40-64 living in specific neighborhoods of northern Manhattan who have not been tested for APOE. It's not open to those with Alzheimer's, a family history of early onset Alzheimer's, or current suicidal thoughts.

Inclusion Criteria

You currently live in specific neighborhoods in New York City including Washington Heights, Inwood, Hamilton Heights, Central Harlem, East Harlem, Morningside Heights, Manhattanville, or Striver's Row.

I am between 40 and 64 years old.

You consider yourself to be Latino or Hispanic.

Exclusion Criteria

I have been tested for the APOE gene.

I have been diagnosed with Alzheimer's disease.

My family has a history of early Alzheimer's that can be passed down.

See 4 more

Treatment Details

Interventions

Disclosure of APOE genotype (Genetic Testing)

Trial OverviewThe study examines the effects on Latinos of learning their genetic risk for late-onset Alzheimer's Disease. Participants will either be told their risk based on ethnicity and family history alone or with added APOE genotype information.

Participant Groups

2Treatment groups

Experimental Treatment

Active Control

Group I: DisclosureExperimental Treatment1 Intervention

Participants will be given information about their risk of Alzheimer's disease based on Latino ethnicity, family history of Alzheimer's disease, and their APOE genotype.

Group II: Non-disclosureActive Control1 Intervention

Participants will be given information about their risk of Alzheimer's disease based on Latino ethnicity and family history of Alzheimer's disease alone.